Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Endocrine Reviews · 2026
DOI: 10.1210/endrev/bnaf036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Reviews, 2026. Verfasst von Jang Won Son und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 219 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach. Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea.
- Diabetes Complications Research Centre, University College Dublin, Dublin D04 C1P1, Ireland.
- Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig 04103, Germany.
- Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum, St. Josef Hospital (Ruhr University Bochum), Bochum 44791, Germany.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul 03080, South Korea.
ORCID-Profile: Jang Won Son, Carel W le Roux, Michael A Nauck, Soo Lim
Zitieren
APA
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026). Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine Reviews. https://doi.org/10.1210/endrev/bnaf036
Vancouver
Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine Reviews. 2026. doi:10.1210/endrev/bnaf036
BibTeX
@article{Son2026,
author = {Son, Jang Won and le Roux, Carel W and Blüher, Matthias and Nauck, Michael A and Lim, Soo},
title = {Novel GLP-1-based Medications for Type 2 Diabetes and Obesity},
journal = {Endocrine Reviews},
year = {2026},
doi = {10.1210/endrev/bnaf036}
}
EUVIMED